| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2). Regaloside B inhibits the expression of iNOS and COX-2, two key enzymes involved in inflammatory responses. By suppressing these inflammatory mediators, the compound reduces the production of nitric oxide and prostaglandins. The compound also exhibits antioxidant activity through free radical scavenging, and demonstrates neuroprotective properties relevant to neurodegenerative disorders.
|
|---|---|
| ln Vitro |
Regaloside B inhibits the expression of iNOS and COX-2, demonstrating anti-inflammatory activity. The compound exhibits notable antioxidant properties by scavenging free radicals. Regaloside B also shows neuroprotective properties, making it a subject of interest in studies related to aging and neurodegenerative disorders. These in vitro activities suggest potential therapeutic applications in inflammatory and neurodegenerative diseases.
|
| ln Vivo |
In vivo, Regaloside B has been investigated for its anti-inflammatory and neuroprotective effects. As a natural phenylethanoid glycoside, it may exert systemic effects through modulation of inflammatory pathways and oxidative stress. The compound's natural origin and multifunctional pharmacological profile highlight its potential in herbal therapeutics and functional food development. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Receptor binding or enzyme inhibition assays can be performed to evaluate the interaction of Regaloside B with its targets. Enzyme activity assays using recombinant iNOS or COX-2 can measure the compound's inhibitory effects on these enzymes. The compound's ability to scavenge free radicals can be assessed using cell-free antioxidant assays such as DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
Cellular assays are used to evaluate the anti-inflammatory and antioxidant activities of Regaloside B. Cultured macrophages (e.g., RAW 264.7 cells) are stimulated with LPS in the presence of increasing concentrations of Regaloside B (typically 1-100 μM). Inhibition of iNOS and COX-2 expression is measured by Western blot or qPCR. Nitric oxide production is measured by Griess assay, and prostaglandin E2 levels are measured by ELISA. Cellular antioxidant activity can be assessed using ROS detection assays.
|
| Animal Protocol |
No specific animal experiments have been reported for Regaloside B in the available literature. For natural anti-inflammatory compounds, typical in vivo efficacy studies would involve murine models of inflammation such as carrageenan-induced paw edema, LPS-induced systemic inflammation, or DSS-induced colitis. The compound would be administered orally or intraperitoneally, and efficacy endpoints would include reduction of inflammatory markers, tissue pathology, and oxidative stress parameters.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Regaloside B have not been fully characterized. The compound has a molecular weight of 442.41 g/mol and molecular formula C20H26O11. It is sparingly soluble in water (11 g/L at 25°C). As a glycoside, it may have moderate oral bioavailability with metabolism in the gut and liver. The compound is stable under recommended storage conditions. Pharmacokinetic studies would be needed to determine absorption, distribution, metabolism, and excretion profiles.
|
| Toxicity/Toxicokinetics |
No specific toxicity data has been reported for Regaloside B. As a naturally occurring phenylethanoid glycoside from medicinal plants, it is generally considered to have low toxicity. Standard toxicity assessments would include evaluation of cytotoxicity in cell lines, genotoxicity assays, and acute and sub-chronic toxicity studies in animal models. The compound is for research use only and not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
It has been reported that lilies and brown lilies contain Regaloside B, and data on its content are available.
Regaloside B (CAS#: 114420-67-6) is a phenylethanoid glycoside isolated from Rehmannia glutinosa and Lilium longiflorum. It has a molecular formula of C20H26O11 and molecular weight of 442.41. The IUPAC name is [(2S)-3-acetyloxy-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-3-(4-hydroxyphenyl)prop-2-enoate. Regaloside B exhibits antioxidant, anti-inflammatory, and neuroprotective properties. It inhibits iNOS and COX-2 expression and scavenges free radicals. |
| Molecular Formula |
C20H26O11
|
|---|---|
| Molecular Weight |
442.41
|
| Exact Mass |
442.148
|
| CAS # |
114420-67-6
|
| PubChem CID |
5459143
|
| Appearance |
White to off-white solid powder
|
| Density |
1.46g/cm3
|
| Boiling Point |
727.5ºC at 760mmHg
|
| Flash Point |
253.8ºC
|
| Vapour Pressure |
3.23E-22mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
31
|
| Complexity |
602
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)OC[C@@H](COC(=O)/C=C/C1=CC=C(C=C1)O)OC2C(C(C(C(O2)CO)O)O)O
|
| InChi Key |
YQKQOLPNKNHLBO-KRJCNZRASA-N
|
| InChi Code |
InChI=1S/C20H26O11/c1-11(22)28-9-14(30-20-19(27)18(26)17(25)15(8-21)31-20)10-29-16(24)7-4-12-2-5-13(23)6-3-12/h2-7,14-15,17-21,23,25-27H,8-10H2,1H3/b7-4+/t14-,15?,17?,18?,19?,20?/m0/s1
|
| Chemical Name |
[(2S)-3-acetyloxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-3-(4-hydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (226.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2603 mL | 11.3017 mL | 22.6035 mL | |
| 5 mM | 0.4521 mL | 2.2603 mL | 4.5207 mL | |
| 10 mM | 0.2260 mL | 1.1302 mL | 2.2603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
